Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary Guangzhou Apichope Pharmaceutical Co., Ltd. has received acceptance from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug APH03621 tablet, and has received the "Acceptance Notice."
APH03621 is a novel oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) developed by the company, intended for the treatment of endometriosis.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。